OUTTHUNDER BETA

ABBV

buy Researched 2026-11-03 20:45 UTC

PriceDayYTD
Nov 2 close 288.84
Now 15:45 ET 285.82
−1.0%+25.1%

Trend

294.89248.22201.55↑ 294.89288.84≤ 281.98Volume52.6MClose21-day50-day200-dayBuy zoneMay 5Aug 5Nov 2

The close of 288.84 sits 2.4% (1.00 ATR) above the rising 21-day average of 281.98, and 7.1% (2.79 ATR) above the rising 50-day average of 269.77. This is an uptrend that is extended from its 50-day average, not a pullback.

Bull case
  • Earnings-driven estimate momentum: Q3 beat (adjusted EPS $3.82 vs about $3.74) and raised 2026 guidance (EPS $13.95–$13.99, revenue about $67.8B) reflect growth in the immunology franchises (Skyrizi +22.9%, Rinvoq +24.3%). Bernstein's FY2026 EPS estimate moved to $13.93 in the same reporting window.
  • Near-term Medicare exposure is limited: Skyrizi and Rinvoq are not in the IPAY 2028 negotiation cycle, which covers Botox for AbbVie. Rinvoq is only a projected IPAY 2029 selection, so the next negotiated price cut is not expected before the February 2027 report.
  • Cash return: The quarterly dividend rises 5.2% to $1.82, first payable with the February 2027 dividend. This supports the long-term holding case, though the payment date is not given.
  • Relative strength vs sector: Over 3 months ABBV is +18.5% against PPH at +10.2% (relative strength +8.2%) and XLV at +13.9%. PPH's 0.76 correlation means the sector is still the main driver, so this is a sector tailwind plus some stock-specific outperformance.
Bear case
  • Extended against its averages: The close is 2.79 ATR above the 50-day average and 1.00 ATR above the 21-day. It is also 2.1% below the 52-week high of 294.89, after a 1-month gain of +9.9%. Entering now means buying near the top of the recent range.
  • Erosion still offsets growth: Humira fell 39.9% in US sales in Q3. Growth in newer products has to keep covering this, and the Zacks Rank #4 (Sell) reflects weak estimate revisions before the print.
  • Q4 guidance sits below consensus: EPS guidance of $3.83–$3.87 is below the $3.89 consensus cited in two items. Q4 revenue guidance of $18.4B is above the $18.3B consensus.
  • Long-run Medicare risk: The 10-K warns that more large products may be selected in future years, and Rinvoq is a projected IPAY 2029 candidate. The thesis research does not give timing for new IL-23 or JAK competitors, so it cannot say whether competition will erode Skyrizi or Rinvoq before February 2027. The question is unresolved.
  • Fundamentals not verified: The fundamentals data returned a 404 error, so I have no P/E, margin, debt or book value figures. The 18x forward P/E in a Motley Fool piece is opinion, not verified data.

Evidence caveat: Most of the bullish news is analyst target changes issued in response to the earnings move. They are opinions, not confirmed levels, and I have not used them as triggers. Several are contradicted by the Zacks Rank and the Q4 guidance miss.

Decision

Asked: I don't own it. I'm considering buying it for the long term.

  • Action: buy (staged, starting with half of the intended position)
  • Condition: a daily close at or below 281.98 (the 21-day average, 2.4% / 1.00 ATR below the latest close) before the review-by date.
  • Timing: I would not buy the full position at 288.84. The uptrend and the analyst revisions favor owning the stock, but the price is 2.79 ATR above its 50-day average, and the Q4 guidance miss and erosion risks are not resolved. The cost I accept by waiting is the chance the stock keeps running and I pay more. The cost of acting now is buying an extended stock on thin evidence. For a long-term holder I prefer the pullback, but the pullback is only about 1 ATR away, which is routine.
  • Distance: 2.4% below the latest close, which is 1.00 ATR. A move of this size is routine for ABBV.
  • If-not-met: if the close has not reached 281.98 by 2026-11-25, buy the first half at that session's close. Waiting longer risks paying up for confirmation the trend has already shown. The accepted cost is entering at a higher price.
  • Invalidation: a daily close below the 50-day average of 269.77 (6.6% / 2.79 ATR below the latest close), or evidence that IL-23 or JAK competitor launches will erode Skyrizi or Rinvoq before February 2027.
  • Forecast: 0.55 that ABBV's total return beats SPY's through the first close after the 2027-02-03 earnings report (64 sessions). SPY has a correlation of -0.10 with ABBV, so the comparison is largely a sector and stock-specific call rather than a market-beta call. Humira erosion, the Q4 guidance gap, and unverified fundamentals keep this close to 0.50.

Technical analysis: computed from daily prices as of 2026-11-02. Not an input to the decision above: each is scored against SPY on its own.

  • MACD (12, 26, 9): BULLISH, above its signal line, crossed 18 sessions ago (2026-10-07). Line 6.35, signal 6.22, histogram +0.13 and narrowing.
  • Awesome Oscillator (5, 34): BULLISH, above zero, crossed 34 sessions ago (2026-09-15). +14.46 and falling.
  • Chaikin Money Flow (20): BULLISH, buying pressure: volume is backing the up days, crossed 20 sessions ago (2026-10-05). +0.12 and falling.

Review triggers

  • Review-by: 2026-11-25 (PCE and GDP releases). This is the nearest scheduled market event that could shift the rate and growth backdrop. It is 17 trading sessions after the latest close, so the price triggers below are within 2×√17 ≈ 8.25 ATR.
  • Price-below: 281.98 (21-day average, 1.00 ATR below the close), triggers the staged buy.
  • Price-below (thesis break): 269.77 (50-day average, 2.79 ATR below the close).
  • Price-above: 294.89 (52-week high, 0.31 ATR above the close). A break above this level would confirm the trend, but it makes the entry more expensive.
  • Volume-above: 9,368K shares (90th-percentile session volume). A high-volume session on a down move would warrant re-review.

Scaling in: consider building this entry in parts (dollar-cost averaging) rather than as a single order — for example, split the amount across several sessions or either side of the review date (2026-11-25 (PCE and GDP releases). This is the nearest scheduled market event that could shift the rate and growth backdrop. It is 17 trading sessions after the latest close, so the price triggers below are within 2×√17 ≈ 8.25 ATR.).

Dive deep

Market overview of 2026-11-03 20:27 UTC →